3 Growth Companies With High Insider Ownership Seeing Up To 29% Revenue Growth

In This Article:

As global markets navigate a landscape marked by rate adjustments and sector-specific rallies, the focus remains on growth opportunities amid economic shifts. In this context, companies with high insider ownership and robust revenue growth stand out as compelling prospects, offering insights into potential resilience and alignment of interests between management and shareholders.

Top 10 Growth Companies With High Insider Ownership

Name

Insider Ownership

Earnings Growth

Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3)

11.9%

21.1%

Archean Chemical Industries (NSEI:ACI)

22.9%

34%

Kirloskar Pneumatic (BSE:505283)

30.3%

30.1%

People & Technology (KOSDAQ:A137400)

16.4%

35.6%

Arctech Solar Holding (SHSE:688408)

37.8%

29.8%

Seojin SystemLtd (KOSDAQ:A178320)

30.7%

49.1%

Medley (TSE:4480)

34%

30.4%

HANA Micron (KOSDAQ:A067310)

18.3%

105.8%

Adveritas (ASX:AV1)

21.2%

144.2%

Plenti Group (ASX:PLT)

12.8%

106.4%

Click here to see the full list of 1485 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

Philippine Seven

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Philippine Seven Corporation operates convenience stores in the Philippines with a market cap of ₱113.46 billion.

Operations: The company generates revenue of ₱86.14 billion from its store operations segment.

Insider Ownership: 11.2%

Revenue Growth Forecast: 12% p.a.

Philippine Seven's earnings are forecast to grow at 16.7% annually, outpacing the Philippine market's 11.6%. Recent results show robust growth with second-quarter sales reaching PHP 22.74 billion, up from PHP 19.28 billion year-on-year, and net income rising to PHP 1.12 billion from PHP 1.02 billion. Despite a high return on equity forecast of 25.8%, its dividend yield of 6.4% is not well-covered by earnings, indicating potential financial constraints amidst growth prospects.

PSE:SEVN Earnings and Revenue Growth as at Oct 2024
PSE:SEVN Earnings and Revenue Growth as at Oct 2024

Beijing Sun-Novo Pharmaceutical Research

Simply Wall St Growth Rating: ★★★★★★

Overview: Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is a contract research company focused on drug research and development in China, with a market cap of CN¥4.87 billion.

Operations: The company's revenue is primarily derived from Pharmacy Research Services, which generated CN¥594.85 million, and Clinical Trials and Bioanalytical Services, contributing CN¥434.84 million.

Insider Ownership: 36.7%